CTOs on the Move

Myonexustx

www.myonexustx.com

 
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first-ever, corrective treatments for Limb-girdle muscular dystrophy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Myonexustx raised $60M on 05/08/2018

Similar Companies

Epic Technology Consulting

Epic Technology Consulting is a Villa Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

JHP Pharmaceutical

JHP Pharmaceutical is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kamada

Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company`s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of six other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada`s rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma. Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency and, in addition, its intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.

MassMEDIC

The Heart of Healthtech Beats Here. We proudly serve as the voice of the #healthtech industry in New England, representing companies changing the world.

Precision for Medicine

At Precision for Medicine, we help our pharmaceutical and life sciences clients innovate, develop, and commercialize next generation medical products. Backed by a diverse team of experts across the spectrum of the healthcare marketplace, we provide a comprehensive and integrated set of services that help accelerate research, enable market adoption, enhance patient outcomes, and realize the full commercial potential of new therapies and products.